Cardiff Oncology Future Growth

Future criteria checks 0/6

Cardiff Oncology's revenue and earnings are forecast to decline at 51.6% and 28.9% per annum respectively while EPS is expected to decline by 18.7% per annum.

Key information

-28.9%

Earnings growth rate

-18.7%

EPS growth rate

Biotechs earnings growth	31.1%
Revenue growth rate	-51.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:XE7C - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-78	-195	N/A	3
12/31/2025	0	-58	-95	N/A	3
12/31/2024	0	-45	-52	N/A	4
3/31/2024	1	-40	-31	-30	N/A
12/31/2023	0	-41	-31	-31	N/A
9/30/2023	0	-41	-34	-33	N/A
6/30/2023	0	-40	-33	-33	N/A
3/31/2023	0	-39	-33	-32	N/A
12/31/2022	0	-39	-35	-34	N/A
9/30/2022	0	-39	-33	-32	N/A
6/30/2022	0	-38	-30	-30	N/A
3/31/2022	0	-34	-28	-27	N/A
12/31/2021	0	-28	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-23	-19	-19	N/A
3/31/2021	0	-24	-19	-19	N/A
12/31/2020	0	-23	-17	-16	N/A
9/30/2020	0	-20	-15	-14	N/A
6/30/2020	0	-20	-14	-14	N/A
3/31/2020	0	-17	-13	-13	N/A
12/31/2019	0	-17	-13	-13	N/A
9/30/2019	0	-17	-14	-14	N/A
6/30/2019	0	-16	-14	-14	N/A
3/31/2019	0	-19	-14	-14	N/A
12/31/2018	0	-19	-13	-13	N/A
9/30/2018	0	-18	-13	-13	N/A
6/30/2018	1	-18	-16	-16	N/A
3/31/2018	1	-20	-17	-17	N/A
12/31/2017	1	-25	N/A	-23	N/A
9/30/2017	0	-31	N/A	-29	N/A
6/30/2017	0	-37	N/A	-29	N/A
3/31/2017	0	-39	N/A	-33	N/A
12/31/2016	0	-39	N/A	-31	N/A
9/30/2016	0	-38	N/A	-29	N/A
6/30/2016	0	-31	N/A	-27	N/A
3/31/2016	0	-31	N/A	-24	N/A
12/31/2015	0	-27	N/A	-22	N/A
9/30/2015	0	-25	N/A	-19	N/A
6/30/2015	0	-27	N/A	-17	N/A
3/31/2015	0	-18	N/A	-15	N/A
12/31/2014	0	-14	N/A	-13	N/A
9/30/2014	0	-11	N/A	-11	N/A
6/30/2014	0	-10	N/A	-9	N/A
3/31/2014	0	-14	N/A	-8	N/A
12/31/2013	0	-12	N/A	-7	N/A
9/30/2013	0	-17	N/A	-7	N/A
6/30/2013	1	-13	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XE7C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XE7C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XE7C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XE7C's revenue is expected to decline over the next 3 years (-51.6% per year).

High Growth Revenue: XE7C's revenue is forecast to decline over the next 3 years (-51.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XE7C's Return on Equity is forecast to be high in 3 years time

Cardiff Oncology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.25 loss in 1Q 2023)

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Full year 2023 earnings released: US$0.93 loss per share (vs US$0.89 loss in FY 2022)

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released: US$0.22 loss per share (vs US$0.20 loss in 3Q 2022)

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.24 loss in 2Q 2022)

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$0.89 loss per share (vs US$0.72 loss in FY 2021)

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 3Q 2021)

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.17 loss in 2Q 2021)

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

First quarter 2022 earnings released: EPS: US$0 (vs US$0.14 loss in 1Q 2021)

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Independent Director recently bought €173k worth of stock

Chief Financial Officer recently bought €164k worth of stock

Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.51 loss in 2Q 2020)

Independent Director Gary Jacob has left the company

Independent Director Thomas Adams has left the company

Cardiff Oncology, Inc. Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.41 loss in 1Q 2020)

Independent Director recently bought €86k worth of stock

Full year 2020 earnings released: US$1.08 loss per share (vs US$2.80 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.05

Cardiff Oncology, Inc. Updates Data from Its Phase 2 Metastatic Castrate-Resistant Prostate Cancer Trial Were Featured in A Virtual Oral Poster Presentation At the American Society of Clinical Oncology Genitourinary Cancers Symposium

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

New 90-day low: €10.10

Cardiff Oncology, Inc. Developing New Treatment Options for Cancer Patients in Indications with the Greatest Medical Need

Cardiff Oncology Presents Data That Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from Its Expanded Access Program

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology, Inc. Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

New 90-day high: €14.00

New 90-day high: €13.60

Cardiff Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $87.75 million.

New 90-day high: €6.95

Cardiff Oncology, Inc. Presents Data At ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer

New 90-day high - €6.05

First half earnings released

New 90-day high - €4.54

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies